for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innate Pharma SA

IPH.PA

Latest Trade

6.00EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.55

 - 

9.45

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
6.00
Open
--
Volume
--
3M AVG Volume
3.44
Today's High
--
Today's Low
--
52 Week High
9.45
52 Week Low
4.55
Shares Out (MIL)
64.03
Market Cap (MIL)
389.94
Forward P/E
-71.28
Dividend (Yield %)
--

Next Event

Innate Pharma SA Annual Shareholders Meeting

Latest Developments

More

Innate Pharma Launches Proposed Global Offering And Nasdaq Listing

Innate Pharma SA Sees U.S. IPO Of Up To 10.7 Mln Ordinary Shares

Innate Pharma Files Registration Statement For Proposed IPO In U.S.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Innate Pharma SA

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Industry

Biotechnology & Drugs

Contact Info

117 avenue de Luminy, Bp 30191

+33.4.30303030

http://www.innate-pharma.com

Executive Leadership

Herve Brailly

Chairman of the Supervisory Board

Mondher Mahjoubi

Chairman of the Executive Board, Chief Executive Officer

Irina Staatz-Granzer

Independent Vice Chairman of the Supervisory Board

Laure-Hélène Mercier

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Yannis Morel

Executive Vice President Products Portfolio Strategy & Business Development, Member of the Executive Board

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.1K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (EUR)

2016

0.230

2017

-0.890

2018

0.050

2019(E)

-0.085
Price To Earnings (TTM)
11.67
Price To Sales (TTM)
3.40
Price To Book (MRQ)
2.15
Price To Cash Flow (TTM)
8.74
Total Debt To Equity (MRQ)
18.09
LT Debt To Equity (MRQ)
5.07
Return on Investment (TTM)
15.59
Return on Equity (TTM)
11.23

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up